Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.
作者信息
Capetti Amedeo F, Stangalini Carlo A, Borgonovo Fabio, Mileto Davide, Oreni Letizia, Dedivitiis Gianfranco, Lupo Angelica, Cossu Maria V, Bilardo Lara, Giacomelli Andrea, Galli Massimo, Rizzardini Giuliano
机构信息
1st Division of Infectious Diseases, "Luigi Sacco" University Hospital, Milan, Italy.
"San Giuseppe Moscati" Foundation, Milan, Italy.
出版信息
Clin Infect Dis. 2021 Sep 15;73(6):e1402-e1403. doi: 10.1093/cid/ciab214.
Abstract
摘要
相似文献
1
Impressive Boosting of Anti-S1/S2 Immunoglobulin G Production in Coronavirus Disease 2019 (COVID-19)-experienced Patients After the First Shot of the BNT162b2 Messenger RNA COVID-19 Vaccine.在接种第一剂BNT162b2信使核糖核酸新冠疫苗后，新冠病毒病（COVID-19）康复患者的抗S1/S2免疫球蛋白G产生显著增强。
Clin Infect Dis. 2021 Sep 15;73(6):e1402-e1403. doi: 10.1093/cid/ciab214.
2
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.辉瑞 BNT162b2 mRNA 新冠疫苗接种后体液免疫反应的综合评估：三例病例系列。
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591. doi: 10.1515/cclm-2021-0339. Print 2021 Aug 26.
3
Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.比较 BNT162b2 mRNA 疫苗接种者的恢复期和未接种者的 SARS-CoV-2 抗刺突蛋白 RBD IgG 和中和抗体与 COVID-19 患者的动力学。
BMC Med. 2021 Aug 23;19(1):208. doi: 10.1186/s12916-021-02090-6.
4
A case of sensory ataxic Guillain-Barré syndrome with immunoglobulin G anti-GM1 antibodies following the first dose of mRNA COVID-19 vaccine BNT162b2 (Pfizer).首例接种mRNA新冠疫苗BNT162b2（辉瑞）后出现伴有抗GM1抗体的感觉性共济失调型吉兰-巴雷综合征病例。
QJM. 2022 Jan 21;115(1):25-27. doi: 10.1093/qjmed/hcab296.
5
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
6
Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.有或无前新冠病毒感染启动的情况下，SARS-CoV-2疫苗BNT162b2的抗体依赖性中和能力
J Intern Med. 2021 Dec;290(6):1272-1274. doi: 10.1111/joim.13366. Epub 2021 Aug 2.
7
Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination.产前接种 SARS-CoV-2 BNT162b2 信使 RNA 疫苗后，高效的母胎胎盘转导抗严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）刺突抗体。
Clin Infect Dis. 2021 Nov 16;73(10):1909-1912. doi: 10.1093/cid/ciab266.
8
The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.全国性 BNT162b2 mRNA COVID-19 疫苗接种计划的初步影响。
Int J Infect Dis. 2021 Jul;108:116-118. doi: 10.1016/j.ijid.2021.05.021. Epub 2021 May 13.
9
Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine.高效的母体到新生儿的 SARS-CoV-2 抗体和 BNT162b2 mRNA COVID-19 疫苗的转移。
J Clin Invest. 2021 Jul 1;131(13). doi: 10.1172/JCI150319.
10
Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.BNT162b2信使核糖核酸2019冠状病毒病疫苗在疗养院居民中的体液免疫原性和细胞免疫原性
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147. doi: 10.1093/cid/ciab300.
引用本文的文献
1
A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response.接种后 SARS-CoV-2 血清学检测综述：方法和抗体滴度反应。
Anal Biochem. 2022 Dec 1;658:114902. doi: 10.1016/j.ab.2022.114902. Epub 2022 Sep 17.
2
Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects.BNT162b2 疫苗接种 6 个月后 COVID-19 初治和 COVID-19 既往感染人群抗 S1/S2 IgG 血清水平下降率。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2060018. doi: 10.1080/21645515.2022.2060018. Epub 2022 May 5.
3
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.COVID-19 mRNA 疫苗诱导针对三种 SARS-CoV-2 变体的抗体反应。
Nat Commun. 2021 Jun 28;12(1):3991. doi: 10.1038/s41467-021-24285-4.
4
Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine.用于评估BNT162b2疫苗接种后抗N/S IgG血清阳性的快速侧向流动免疫层析试验：一项横断面研究：BNT162b2疫苗接种后的快速侧向流动免疫层析试验。
J Infect. 2021 Sep;83(3):381-412. doi: 10.1016/j.jinf.2021.05.029. Epub 2021 May 29.
5
One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG.抗 SARS-CoV-2 刺突 IgG 的一年耐久性：来自 anticrown 前瞻性观察研究的初步数据，研究 COVID-19 抗刺突 IgG 的一年耐久性。
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.023. Epub 2021 May 27.
Zotero 插件